IP Verse

Janssen Oncology competitive analysis

Loading summary...

Latest patents of Janssen Oncology opposed by its competitors

Explore Janssen Oncology's recently opposed patents, revealing key competitive challenges and strategic patent disputes in the industry. Track oppositions filed by competitors to understand technology battlegrounds and assess potential risks.

Last updated on: Oct 23, 2025
Patent NumberGrant DateTitleTotal Oppositions
EP2478907
Apr 14, 2021Methods And Compositions For Treating Cancer22

Latest publications and patents of Janssen Oncology New

Explore the latest publications and patents granted to Janssen Oncology, showcasing their recent innovations and technological advancements.

Last updated on: Oct 17, 2025
Publication NumberPublication DateTitleLegal Status

Get instant update for new patents of Janssen Oncology

EP2478907
Apr 14, 2021Methods And Compositions For Treating CancerRevoked

Latest PTAB cases involving Janssen Oncology

Discover the latest PTAB cases involving Janssen Oncology, highlighting their recent legal challenges and patent disputes.

Last updated on: Oct 23, 2025
Proceeding NumberFiling DatePetitionerRespondentStatus

Get alerts for PTAB Cases involving Janssen Oncology

IPR2017-00853Feb 8, 2017ACTAVIS LABORATORIES FLJANSSEN ONCOLOGYFinal Written Decision
IPR2016-01582Aug 10, 2016WOCKHARDT BIOJANSSEN ONCOLOGYFinal Written Decision
IPR2016-01332Jun 30, 2016MYLAN PHARMACEUTICALSJANSSEN ONCOLOGYFinal Written Decision
IPR2016-01317Jun 29, 2016ARGENTUM PHARMACEUTICALSJANSSEN ONCOLOGYFinal Written Decision
IPR2016-00286Dec 4, 2015AMERIGEN PHARMACEUTICALSJANSSEN ONCOLOGYFinal Written Decision

Peer Comparison New

IP litigation analysis comparing Janssen Oncology with top 3 competitors. Includes complete PTAB case data and opposition data from 2018 onwards.

Last updated on: Oct 23, 2025
CompanyOppositions FiledOppositions FacedPTAB Cases FiledPTAB Cases Faced
JANSSEN ONCOLOGY - 22 - 5
ACCORD HEALTHCARE39 - 4 -
ACTAVIS LABORATORIES FL - - 1 -
ALFRED E TIEFENBACHER443 - -